Core Viewpoint - The company has announced the establishment of a new investment fund focused on the medical sector, which is expected to enhance its business operations and financial efficiency [1] Group 1: Investment Details - The company will participate as a limited partner in the Chengdu Rongchuang Gangtong Equity Investment Fund Partnership, contributing RMB 150 million, which represents 30% of the total committed capital of RMB 500 million [1] - The fund aims to invest in areas such as medical devices, medical equipment, and medical services, indicating a strategic focus on expanding into new business domains [1] Group 2: Future Implications - This investment is anticipated to positively impact the company's future development by improving capital utilization efficiency and supporting sustainable growth [1]

证券代码：301515 证券简称：港通医疗 公告编号：2025-055 四川港通医疗设备集团股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"港通医疗"） 于 2025 年 9 月 3 日召开第五届董事会第五次会议，审议通过了《关于与专业投 资机构共同投资设立基金的议案》，同意公司与成都梧桐树创新创业投资合伙企 业（有限合伙）（以下简称"成都梧桐树"）、简阳市空天产业投资发展有限公 司（以下简称"空天产投"）、成都技转创业投资有限公司（以下简称"成都技 转"）、意扬企业管理（成都）有限责任公司（以下简称"意扬企管"）共同投 资设立成都蓉创港通股权投资基金合伙企业（有限合伙）（暂定名，最终以市场 监督管理部门核准的名称为准，以下简称"基金""合伙企业"），基金认缴出 资总额为人民币 50,000 万元，其中公司作为有限合伙人以自有资金出资人民币 15,000 万元，占基金认缴出资总额的 30.00%。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-053 四川港通医疗设备集团股份有限公司 关于2024年第二次回购公司股份进展的公告 二、其他说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召开第四届董事会第十七次会议和第四届监事会第十七次会议，审议通过 《关于 2024 年第二次回购公司股份方案的议案》，公司拟使用不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）的自有资金和专项回购贷款 资金以集中竞价交易的方式回购公司已发行的人民币普通股（A 股）股票，回购 价格不超过人民币 28.49 元/股（含），回购的股份将用于实施员工持股计划或 股权激励。本次回购股份的实施期限为自公司董事会审议通过本次回购股份方案 之日起不超过 12 个月。具体回购股份的数量以回购期满或回购完毕时公司实际 回购的股份数量为准。 公司于 2024 年 11 月 8 日召开 2024 年第一次临时股东会，审议通过《关于 公司 2024 年前三季度利润分 ...

四川港通医疗设备集团股份有限公司（以下简称"公司"）第五届董事会第 五次会议于 2025 年 9 月 3 日在公司会议室以现场结合通讯的方式召开。本次会 议通知于 2025 年 9 月 2 日以通讯方式发出，会议应出席董事 9 人，实际出席董 事 9 人（其中：刘煜强先生、魏勇先生、陈叙先生、姚刚先生、周正女士、赵尘 女士以通讯表决方式出席会议）。会议由董事长陈永先生召集并主持，财务总监 张秋先生列席了本次会议。本次会议的召集、召开符合《公司法》和《公司章程》 的有关规定，会议合法有效。 一、董事会会议审议情况 证券代码：301515 证券简称：港通医疗 公告编号：2025-054 四川港通医疗设备集团股份有限公司 第五届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 表决结果为：同意 9 票，反对 0 票，弃权 0 票。 二、备查文件 1、第五届董事会第五次会议决议。 特此公告。 四川港通医疗设备集团股份有限公司董事会 2025 年 9 月 3 日 经过各位董事认真审议，本次会议形成如下决议： （一）审议通过《关于与专业投资机构共同 ...

证券日报网讯港通医疗（301515）9月2日在互动平台回答投资者提问时表示，截至2025年8月29日股东 总户数为7804户。 ...

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 港通医疗9月2日披露，截至8月31日公司股东户数为7804户，较上期（8月20日）减少886户，环比降幅 为10.20%。这已是该公司股东户数连续第2期下降。 证券时报·数据宝统计，截至发稿，港通医疗收盘价为21.41元，下跌1.97%，本期筹码集中以来股价累 计下跌9.74%。具体到各交易日，2次上涨，7次下跌。 融资融券数据显示，该股最新（9月1日）两融余额为5176.48万元，其中，融资余额为5176.48万元，本 期筹码集中以来融资余额合计减少473.92万元，降幅为8.39%。 公司发布的半年报数据显示，上半年公司共实现营业收入2.65亿元，同比下降39.29%，实现净利 润-840.44万元，同比下降154.53%，基本每股收益为-0.0865元。（数据宝） （文章来源：证券时报网） ...

Core Viewpoint - The company, Sichuan Portong Medical Equipment Group Co., Ltd., is engaged in the medical device industry, focusing on providing medical gas systems and clean operating room solutions for healthcare institutions. The company has recently announced a share buyback plan and has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, indicating its strong market position and innovation capabilities [2][4]. Group 1: Company Overview - Sichuan Portong Medical Equipment Group Co., Ltd. was established on January 13, 1998, and went public on July 25, 2023. The company is headquartered in Chengdu, Sichuan Province, and its main business involves providing comprehensive medical engineering solutions centered on medical gas systems and clean operating rooms [8]. - The company's revenue composition includes: 55.69% from medical clean equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [9]. Group 2: Financial Performance - For the first half of 2025, the company reported revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to shareholders of -8.4044 million yuan, a year-on-year decrease of 154.53% [9]. - The company has distributed a total of 48.9973 million yuan in dividends since its A-share listing [10]. Group 3: Market Activity - On September 1, the company's stock price increased by 0.05%, with a trading volume of 37.3246 million yuan and a turnover rate of 2.70%. The total market capitalization is 2.184 billion yuan [1]. - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title indicating strong innovation and market share [4]. Group 4: Recent Developments - The company has developed the Portong Cloud Monitoring Platform, which utilizes advanced IoT technology and online cloud monitoring to provide real-time monitoring solutions for medical equipment in hospitals [3]. - A share buyback plan has been announced, with a total funding amount not less than 50 million yuan and not exceeding 100 million yuan, with a maximum buyback price of 28.49 yuan per share [4].

Core Viewpoint - 港通医疗 (301515) reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1]. Financial Performance - Total revenue for the first half of 2025 was 265 million yuan, a decrease of 39.29% year-on-year [1]. - The net profit attributable to shareholders was -8.4044 million yuan, representing a decline of 154.53% year-on-year [1]. - In Q2 2025, total revenue was 241 million yuan, down 33.22% year-on-year, and the net profit attributable to shareholders was -9.9834 million yuan, a decrease of 312.13% year-on-year [1]. Cost Structure - The proportion of operating expenses (three fees) increased significantly, with total financial, sales, and management expenses reaching 38.9334 million yuan, accounting for 14.68% of total revenue, an increase of 85.64% year-on-year [1]. - The gross profit margin was 22.09%, up 28.56% year-on-year, while the net profit margin was -3.45%, a decrease of 197.7% year-on-year [1]. Balance Sheet Metrics - Cash and cash equivalents amounted to 695 million yuan, a slight increase of 0.86% year-on-year [1]. - Accounts receivable decreased to 724 million yuan, down 6.30% year-on-year [1]. - Interest-bearing liabilities rose to 266 million yuan, an increase of 88.20% year-on-year [1]. Earnings and Cash Flow - Earnings per share were -0.09 yuan, a decline of 156.13% year-on-year [1]. - Operating cash flow per share was -0.39 yuan, down 41.11% year-on-year [1]. - The net asset value per share was 12.17 yuan, a decrease of 6.77% year-on-year [1]. Business Evaluation - The company's return on invested capital (ROIC) was 0.64%, indicating weak capital returns [4]. - Historical data shows a median ROIC of 12.41% since the company went public, with the worst year being 2024 [4]. - The company relies heavily on research and marketing for its performance, necessitating a deeper analysis of these drivers [4].

Group 1 - The core viewpoint of the article highlights the financial performance of 港通医疗 (SZ 301515), which reported a significant decline in revenue and incurred a net loss in its latest half-year earnings report [1] - For the first half of 2025, the company recorded an operating revenue of approximately 265 million yuan, representing a year-on-year decrease of 39.29% [1] - The net profit attributable to shareholders was a loss of approximately 8.4 million yuan, with basic earnings per share reflecting a loss of 0.0865 yuan [1]

Group 1 - The core point of the article is that 港通医疗 (SZ 301515) held its fifth board meeting on August 27, 2025, to review the 2025 semi-annual report and related documents [1] - For the first half of 2025, the revenue composition of 港通医疗 is as follows: medical clean equipment and systems accounted for 55.69%, medical gas equipment and systems accounted for 37.3%, sales of medical devices and other products accounted for 4.06%, operation and maintenance services accounted for 2.81%, and other businesses accounted for 0.14% [1]